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The Czech Society of Cardiology and the Czech Society for Hypertension provide an expert
consensus statement on the implementation of catheter based renal denervation in the
Czech Republic. Conclusion: until additional and/or larger randomized clinical trials
confirm (or not) the promising results of initial studies, renal denervation can be performed
exclusively as part of specific research protocols, approved by ethical committees. Renal
denervation should be performed only in tertiary centers with ongoing research and
publication activity to guarantee, that the results will be objectively and critically
evaluated. It is unethical to promote this method already today (early 2012) for routine
hypertensive patients as a standard (proven) part of their treatment. Each patient must be
informed, that renal denervation still is in the phase of clinical research.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Results of clinical trials with renal
denervation
The concept of catheter-based sympathetic renal denervation
(the RDN) as amethod for treatment of resistant hypertension
has been subjected to clinical testing in two multicentre
trials—Symplicity HTN-1 (proof of concept) and Symplicity
HTN-2 (randomized controlled study).ch Society of Cardiology.
ical Faculty of Charles U
P. Widimsky´).1.1. The Symplicity HTN-1 trial
This non-randomized multicentre trial [1] should assess
effectiveness and safety of catheter-based renal sympathetic
denervation. 50 patients at five Australian and European
centers were enrolled between the year 2007 and 2008, 5
patients were than excluded for unsuitable anatomy of renal
arteries. 45 patients received catheter-based renal denervation
treatment with subsequent 1 year follow-up. The including
criterion was systolic blood pressure Z160mmHg on three or
more antihypertensive medications, including diuretics. PrimaryPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
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safety of the method at 1, 3, 6, 9 and 12 months after the
procedure. Secondary aims were to evaluate renal functions
(glomerular filtration) and noradrenaline release after renal
denervation performance. Significant decrease in systolic and
diastolic blood pressure of 14 mmHg and 10 mmHg in the first
month after treatment and 27 mmHg and 17 mmHg in 12
months was showed. Recently published results of two years
follow-up of extended group of 153 patients (decrease in blood
pressure of 32 mmHg and 14mmHg) suggest for long-term
beneficial effect of treatment on blood pressure level [2]. In six
of 45 patients (13%) the decrease of systolic blood pressure was
less than 10mmHg and they were identified as non-responders.
In control group of five patients who did not receive renal
denervation (excluded for anatomical reasons) had increase in
systolic and diastolic blood pressure of þ3/2 and þ26/þ17 at 1
and 9 months, respectively. Postprocedural lower sympathetic
activity, expressed as significant reduce of noradrenaline renal
spillover of 47%, was found. Renal functions were not sig-
nificantly changed. In 43 of 45 patients cathether-based renal
sympathetic denervation was performed with no complica-
tions. Renal artery dissection during catheter insertion which
required denervation treatment delay occurred in one patient. It
was treated with stenting of renal artery with no further
complications or prolonged hospitalization time. Second patient
had pseudoaneurysm of femoral artery at the injection site that
was successfully treated conservatively.
1.2. The Simplicity HTN-2 trial
This is multicentre, prospective, randomized trial [3] that
includes 106 patients with systolic blood pressure 160 mmHg
or more (150 mmHg or more for patients with type 2 diabetes
mellitus) treated with combination of three or more anti-
hypertensive medication, were randomly allocated in a one-
to-one ratio into treated group – undergoing renal denerva-
tion (previous medical treatment was not interrupted) and
control group – pharmacotherapy (maintain previous treat-
ment). The primary endpoint was change in office-based
blood pressure measurement at 6 months after randomiza-
tion. Secondary endpoints were immediate and long-term
safety of renal denervation defined as glomerular filtration
reduce 425% or new renal artery stenosis 460% on angio-
graphy after 6 months. Other secondary endpoints were also
composite cardiovascular index (myocardial infarction, sud-
den death, heart failure, cerebral ischemia, peripheral arteries
revascularization, etc.), changes in 24-h ambulatory blood
pressure measurement, incidence of decrease in blood
pressure 410 mHg, etc. 100 of 106 initially randomized
patients were finally evaluated, six patients were excluded
because of preterm end up with study or because they did not
show up at follow-up meeting. Office-based blood pressure
measurement in the renal denervation group reduced by
32/12 mmHg from initial 178/96 mmHg (po0.0001 for both
systolic and diastolic pressure). Whereas in control group
(pharmacotherapy) the change in blood pressure was
1/0 mmHg from initial 178/97 mmHg (p ¼ 0.77 for systolic
and p ¼ 0.83 for diastolic pressure). Similar blood pressure
changes, only lower in absolute numbers, were noticed in 24-
h blood pressure measurements. Reduction in systolic bloodpressure more than 10 mmHg or more had 41.8% patients in
treated group compared with 18.3% in control group, 19.4%
patients treated with renal denervation and 3.6% patients
from pharmacotherapy group achieved required systolic
blood pressure level of 140 mmHg or less. There were not
noted any serious complications related to catheter-based
renal sympathetic denervation. As insignificant events related to
catheter-based treatment were found: one pseudoaneurysm of
femoral artery at the injection site, one postprocedural blood
pressure drop, one urinary tract infection, one case of para-
esthezia and backache. All these events were successfully
treated by standard therapy and did not lead to any other
complications. There were no changes in renal functions
between two groups. One patient from denervation group had
progression of an underlying atherosclerotic lesion in renal
artery at 6 months but required no intervention. The lesion was
in point of artery where the radiofrequency energy was not
applied. No differences were found in composite cardiovascular
events between treated and control group.
On the base of results of these trials their authors assess
catheter-based renal denervation as safe method for achiev-
ing the significant lasting reduction in blood pressure at
patients with resistant hypertension.2. Clinical indications
Renal denervation still is in the late clinical research phase.
What we call here ‘‘clinical indication’’ is based on criteria
used in Symplicity HTN 1 and 2 trials [1–3] that brought the
most significant findings for this type of treatment of
resistant hypertension. The patient is indicated for RDN by
a hypertension specialist (internist, cardiologist or nephrolo-
gist); it is optimal when the patient is indicated and long-term
monitored in specialized centers for hypertension. Patient
should be checked repeatedly in the same center before
indication, preferably at least for six months. It is important
that patient is monitored and sent by other physician than
who will perform the procedure. The physician must verify
patient adherence to treatment using methods that are
available (counting tablets remaining from the last visit,
monitoring drug levels, electronic drug use monitoring) and
consider whether the patient does not commit purposeful
behavior (e.g. not using medication prior to disability pension
application). Patient must meet the below criteria of blood
pressure (BP) while stable treated with minimal three anti-
hypertensive drugs from different classes, including diuretics,
in optimal doses. When measuring BP in office it should be
measured 3 times in a sequence and consider the average of
the second and third measurements. Patient should take his
medication the days of clinical checks (morning medication
using before control) and also the day of ambulatory BP
monitoring. 24-h ambulatory blood pressure monitoring
(ABPM) was not performed systematically in Symplicity HTN
1 and 2 trials, but we consider it necessary to exclude isolated
clinical hypertension (so-called white coat hypertension)
because of significantly better prognosis of this type of
hypertension compared with full hypertension and that it is
not clear whether such patient would benefit from RDN.
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daytime and at least every 30 min during the night period.
Criteria for RDN indication are1. good adherence to treatment,2. hemodynamic stability during follow-up,3. age 18–85 years,4. office-based systolic BPZ160mmHg (average of three visits)
while the average systolic BP for 24 h at ABPM is Z140
mmHg when taking at least three types of antihypertensive
drugs, including diuretics, in optimal doses, and5. estimated glomerular filtration rate (MDRD)Z1.0 ml/s/
1.73 m2.
In cases of clinical indication, the reimbursement negotia-
tions with health care insurance payers are pending.3. Research indications
Research indications are based on comprehensive pathophysio-
logical perspective on the role of renal sympathetic innervation
as a trigger andmaintenance factor of resistant hypertension but
also its influence on number of other diseases that are
significantly associated with RAAS activity. For diagnosis where
the indication is not yet approved and also for those using
alternative technologies with absence of CE certificate renal
denervation could be performed exclusively within the proper
research protocol administered according to strict principles of
good clinical practice. Each of these protocols must be approved
by ethics committee of the department, patient must have
detailed written information about the nature and risks of the
research and must confirm in writing form its consent with the
procedure defined in the research indication.
Currently, RDN research is focused especially on1. resistant hypertension in patients in hemodialysis program,2. possible influence on sleep apnea syndrome,3. advanced heart failurewith left ventricle systolic dysfunction,4. recurrent symptomatic heart failure with preserved func-
tion of left ventricle,5. influence on insulin resistance and atherosclerosis, and6. resistant hypertension with office-based systolic BPZ140
mmHg and average systolic BP for 24 h at ABPMZ130mmHg
when taking at least three types of antihypertensive drugs.
Payment by health care insurance payers is not expected in
research indications.4. Risks and contraindications
RDN is like any other intervention performed via arterial
approach associated with general risks of catheterization (access
site hematoma, AV fistula, aneurysm, artery dissection, artery
perforation, etc.) and also with some specific complications.
Specific risks associated with RDN are1. renal artery perforation due to application of radiofre-
quency (RF) energy,2. adrenal artery occlusion during RF application to its take-
off from the renal artery,3. stenosis/occlusion of renal artery (more likely in renal
arteries with diametero4 mm),
4. extended spasm of renal artery,5. pain after RF energy application, and6. dissection of renal artery due to catheter manipulation.
Contraindications to RDN Secondary hypertension.
J Nefrogenic hypertension.
J Endocrine conditioned hypertension.
J Hypertension induced by drugs that cannot be discon-
tinued (e.g. corticosteroids).
J Hypertension in untreated sleep apnea syndrome. History of acute coronary syndrome or stroke in last six
months. Implantable cardioverter-defibrillator (pacemaker is rela-
tive contraindication). Hemodynamically significant valvular heart disease.
 Type 1 diabetes mellitus.
 Type 2 diabetes mellitus with developed organ complica-
tions such as proteinuria 41 g/24 hod or proliferative
retinopathy. Morbid obesity (BMI 35 kg/m2 or more).
 Pregnancy (current or planned at the time within six
months after the procedure). Other diseases that significantly affect life expectancy
(life expectancy less than two years) or quality of life
(in particular a significant decline in cognitive functions). Renal insufficiency with GFRo1.0 ml/s/1.73 m2.
 Renal arteries with unsuitable morphology (short course,
massive calcification, stenosis, previous PTA) or with diame-
tero4mm.
5. Patient preparation. Renal denervation
procedure
Patient who fulfills clinical indication criteria for renal denerva-
tion [4] and/or inclusion criteria for specific research project is
admitted to hospital for 1–2 days. The organizational manage-
ment of the hospitalization is very similar to the one of elective
percutaneous coronary intervention (PCI) via femoral artery.
Patient preparation for intervention is analogical, too: patient
should have an empty stomach and should be well hydrated
before the procedure (drinks but no food prior to intervention
are allowed). Hypertension pharmacotherapy should remain
unchanged before (and after) the intervention and patient
should take acetylsalicylic acid prior to the procedure. At the
beginning of the intervention, intraarterial bolus of 100 IU/kg of
heparin is administered via catheter.
Catheter-based renal denervation (RDN) starts with introduc-
tion of catheter sheath to femoral artery (technique identical to
coronary angiography or PCI). Afterwards, pigtail catheter-based
angiography of the abdominal aorta aiming to depict both
(and any accessory) renal arteries is performed. Angiography
must confirm that renal arteries considered for denervation
are at least 4mm in diameter. Their length should at least 2 cm
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be present. The type of guiding catheter is selected in
accordance with the anatomy of the origin of renal arteries
(the most common types of catheters are IMA, RDN1 or RDC1
with length of 45–55 cm, width of 6 F). The catheter is then
introduced to the origin of renal artery (usually starting with
left one).
At this moment, the sedation/analgesia should be adminis-
tered. The most frequently used analgesic agent is ketamine
and sedative propofol. Alternatively, combination of fentanyl
and midazolam may be used. The sedation/analgesia should
be performed by an anesthesiologist or an intensivist with a
sufficient experience with its administration. Since the
ablation itself is usually accompanied by severe pain in
lumbar area, efficient sedation/analgesia is essential.
A special ablation catheter Symplicitys, connected to radio-
frequency energy generator is then introduced to the femoral
artery via guiding wire. This ablation catheter is currently a sole
device approved for the intervention. The distal end of the
catheter is introduced close to the point of renal artery
branching and then bent or rotated until it touches, but not
overly presses the wall of the artery. Afterwards, radiofrequency
energy is applied for 120 s. During a correctly performed
ablation, the temperature at the ablation spot should rise to
approx. 45–65 1C (never higher than 70 1C). This can be
monitored (together with the impedance changes) on the display
of the ablation device. The generator switches off automatically
after 120 s of ablation, or after reaching the maximal power of
8W, respectively. It equally turns off automatically when the
temperature rises insufficiently (it indicates the absence of
contact between the catheter and arterial wall). This procedure
is repeated 4–6 while pulling out and rotating the ablation
catheter. The ablation spots in the renal artery roughly follow a
spiral contour. The distance between single ‘‘ablation spots’’
should be at least 5mm. The last ablation spot (closest to the
aorta) should be located on the proximal cranial wall of the renal
artery, as the density of sympathetic nervous plexus is the
highest there. After the last ablation and removal of the ablation
catheter, selective angiography of this renal artery is performed
in order to rule out possible complication [5].
The same method applies to the second renal artery (after
verifying the heparinization effectiveness using the ACT—target
valuesZ250). Considering higher complications rate for renal
arteries thinner than 4mm, currently it is not recommended to
target these arteries. There is so far no evidence concerning the
course of action for patients with multiple renal arteries, where
on every side only one has diameter of 4 mm or greater. Some
workplaces do not indicate these patients for RDN at all, some
perform RDN only on arterieswith sufficient diameter and leave
out narrower arteries. This method is safe; nevertheless, it is
unknown whether it is effective.
Apart from the mentioned material there should always be
renal stents of an appropriate size available (in case of
dissection caused by a guiding or ablation catheter) and a
super-thin (0.014 in.) guiding wire. Continuous monitoring of
ECG, respiratory rate and invasively measured aortic blood
pressure during the intervention should be a matter of course.
The entire intervention (from the arterial puncture until the
removal of all catheters form the sheath) lasts usually
45–60 min and during its performance 60–100 ml of contrastagent is administered (volume prior to dilution). The contrast
agent is diluted in saline solution 1:1.
After the procedure, the patient must be monitored until the
complete retreat of sedation/analgesia. The regimen after-
wards resembles to the regimen following elective PCI (care
for groin puncture site and monitoring of diuresis). The
patient should be followed up at the center providing the
RDN and/or by a hypertension specialist who indicated the
intervention. The antihypertensive medication should re-
main unchanged, only when there is a significant long-term
drop in blood pressure after RDN, the dosing or number of
antihypertensive drugs may be reduced gradually. The
decrease of blood pressure never occurs immediately after
the RDN (any instantaneous pressure reduction is more likely
associated with the sedation/analgesia than with the effect
of RDN itself); it develops weeks to months following the
RDN. The follow-up on the outpatient basis should last not
less than 2 years after the intervention (the blood pressure
values including the ambulatory monitoring, renal functions
monitoring, diabetes management), it is advisable to check
the renal arteries morphology (ultrasound, computed tomo-
graphy or magnetic resonance) 6–12 months after the
RDN. The acetylsalicylic acid intake throughout 4 weeks
following the intervention is an important preventive mea-
sure of thrombotic complications. First follow-up should
occur up to one month after the procedure and besides the
clinical check-up it should involve common laboratory tests
such as renal markers and mineralogram. Further clinical
follow-ups should be provided in minimum intervals of 6
months.6. Qualification criteria for physicians taking
part in indication process, performing RDN
procedures and responsible for patients follow-up
The catheter-based renal denervation is a typical multi-
disciplinary procedure. Physicians experienced in diagnostics
and treatment of severe arterial hypertension should take part
in the indication process (preferably working at specialized
hypertension centers in Czech Republic) which possesses the
‘‘Hypertension center of Excellence’’ certificate of the European
Society of Hypertension (see www.eshonline.org), that means
internists, cardiologists and nephrologists.(a) The intervention should be carried out by a physician with
the sufficient experiencewith the intravascular interventions
and transarterial access. Interventional cardiologists are
usually the most experienced in transfemoral access (license
no. F010 of the Czech Medical Chamber) and this specializa-
tion is the most involved in the RDN progress worldwide.
Regarding the experience in radiofrequency ablation, other
group of physicians capable of this intervention are cardiol-
ogists specialized in arrhythmology (license no. F014).
Naturally, the most skilled in renal arteries interventions
are interventional angiologists (license no. F021) or interven-
tional radiologists (board certification in interventional
radiology). Two criteria should be taken into consideration
when deciding who from these specialists would perform
the intervention at the particular hospital: (1) extensive
Table 1
Personnel requirements Material equipment Minimal numbers of
invasive procedures
At least 3 interventional cardiologists (license
F010)
At least 2 catheterization laboratories (angiography and
coronary angiography, electrophysiology)
4500 PCI/year
At least one electrophysiologist (license F014) RDN must be performed in a room properly equipped
for angiography, with invasive pressure monitoring and
central oxygen supply system
4100 RF ablations/year
At least one interventional angiologist (license
F021) or interventional radiologist (board certified)
RF generator compatible with Symplicity catheters
(generator used in cardiac electrophysiology is not
suitable)
425 renal angiographies
and/or renal arteries
interventions per year
At least one cardiologist, internist or nephrologist
specialized in hypertension treatment (CˇSH
member, center for hypertension)
Internationally certified ambulatory blood pressure
monitoring device
Anesthesiologist or intensivist to assist in all RDN
interventions
Further personnel requirements: see
‘‘requirements for cardiovascular centers’’
Further material equipment: see ‘‘requirements for
cardiovascular centers’’
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artery, and (2) capability of systematic scientific research and
critical analysis of the results including publication activity
(this particular criterion should apply until the definitive
establishment of RDN in the clinical practice and the
intervention routine coverage by health insurance).(b) The sedation/analgesia throughout the procedure should
be administered by an experienced intensivist or anesthe-
siologist.(c) Patients’ follow-up after the intervention should be pro-
vided by the indicating physician (internist, cardiologist,
nephrologist) within hypertension centers (see above) or
cardiologist at the intervening center.
7. Personnel and equipment requirements for
the departments authorized to provide RDN
There are certain minimal requirements for personnel,
material equipment and quantity of key interventions
provided by the departments (Table 1). In general it is possible
to say that the catheter-based renal denervations may be
performed only at specialized tertiary cardiovascular centers
(see their list in the Journal of the Czech Ministry of Health [6].
Apart from the fact that the departments providing RDNmust
be on this Ministry of Health list, they must fulfill following
additional requirements (Table 1).8. Conclusion
It is essential, that until additional and/or larger randomized
clinical trials confirm (or not) the promising results of initial
studies (and decidewhether this promisingmethodwill become
a standard part of the treatment strategy for severe resistant
hypertension), renal denervation can be performed exclusively
as part of specific research protocols, approved by ethicalcommittees. Renal denervation should be performed only in
tertiary centers with ongoing research and publication activity
to guarantee, that the results will be objectively and critically
evaluated. It is unethical to promote this method already today
(early 2012) for routine hypertensive patients as a standard
(proven) part of their treatment. Each patient must be informed,
that renal denervation still is in the phase of clinical research.
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